The authors would like to make corrections to a recently published paper [1].
1. Acknowledgment of the Web Resource
The authors wish to acknowledge the web resource at https://www.marinepharmacology.org/ (accessed on 30 September 2022) [2] as the source of the information presented in Table 3. We apologize for this unintentional omission.
2. Text Correction
In Table 3, the NCT codes listed below have been corrected.
| Names of Marine Natural Products | Wrong or Incomplete NCT Codes | Corrected NCT Codes |
| Phase III | ||
| Plitidepsin (depsipeptide) | [NCT0478455] | [NCT04784559] |
| Marizomib | [NCT03345095] | [NCT00667082] [NCT03345095] |
| Phase II | ||
| RC88 (MMAE) | [NCT0417584] | [NCT04175847] |
| ARX788 (auristatin variant) | [NCT03319628] | [NCT04829604] |
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original publication has also been updated.
References
- Haque, N.; Parveen, S.; Tang, T.; Wei, J.; Huang, Z. Marine Natural Products in Clinical Use. Mar. Drugs 2022, 20, 528. [Google Scholar] [CrossRef] [PubMed]
- Marine Pharmacology. Available online: https://www.marinepharmacology.org/ (accessed on 30 September 2022).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).